Volume 9 Number 1 2026
Microbial Bioactive Metabolites in Cystic Fibrosis: Drivers of Chronic Lung Infection and Novel Therapeutic Targets
Nafiz Tareq Hasnain 1*, Manish Mittal 1, Pallab Paul 1
Microbial Bioactives 9 (1) 1-8 https://doi.org/10.25163/microbbioacts.9110765
Submitted: 08 April 2026 Revised: 21 May 2026 Accepted: 05 June 2026 Published: 07 June 2026
Cystic fibrosis (CF) lung disease has traditionally been understood as a consequence of defective ion transport, impaired mucociliary clearance, and persistent bacterial colonization. Yet recent advances in metabolomics, microbiome science, and immunology suggest that this explanation, while still fundamentally valid, may capture only part of the disease process. Increasingly, the CF airway is being recognized as a metabolically active ecosystem in which host-derived lipids, microbial metabolites, inflammatory mediators, and immune signaling pathways interact continuously to shape chronic pulmonary injury. This narrative review synthesizes current evidence regarding microbial bioactive metabolites and their contribution to airway inflammation, pathogen adaptation, oxidative stress, and therapeutic resistance in CF. Particular attention is given to sphingolipid dysregulation, short-chain fatty acids, quorum-sensing molecules, immunometabolites such as succinate and itaconate, and gut–lung axis signaling. The review further explores the growing therapeutic relevance of natural bioactive compounds, sphingolipid modulators, and CFTR-targeted therapies in controlling chronic inflammatory and metabolic dysfunction. Collectively, the evidence suggests that microbial metabolites are not passive byproducts of infection but active regulators of airway ecology and disease persistence. Although important mechanistic uncertainties remain, emerging metabolomic insights may ultimately help redefine CF management through precision immunometabolism and multi-target therapeutic strategies aimed at disrupting the metabolic conditions that sustain chronic airway disease.
Keywords: Cystic fibrosis, Microbial bioactive metabolites, Immunometabolism, Sphingolipids, Pseudomonas aeruginosa, Chronic lung inflammation, Precision therapeutics
Aureli, M., Schiumarini, D., Loberto, N., Bassi, R., Tamanini, A., Mancini, G., ... & Sonnino, S. (2016). Unravelling the role of sphingolipids in cystic fibrosis lung disease. Chemistry and Physics of Lipids, 200, 94-103. https://doi.org/10.1016/j.chemphyslip.2016.08.002
Bahri, S., Refini, R. M., d'Alessandro, M., Bergantini, L., Cameli, P., Vantaggiato, L., Bini, L., & Landi, C. (2017). The efficacy of plant extract and bioactive compounds in the treatment of pulmonary fibrosis. Biomedicine & Pharmacotherapy, 93, 666-673. https://doi.org/10.1016/j.biopha.2017.06.052
Bardin, P., Marchal-Duval, E., Sonneville, F., Blouquit-Laye, S., Rousselet, N., Le Rouzic, P., ... & Tabary, O. (2018). Small RNA and transcriptome sequencing reveal the role of miR-199a-3p in inflammatory processes in cystic fibrosis airways. Journal of Pathology, 245(4), 410-420.
https://doi.org/10.1002/path.5095
Bargagli, E., Refini, R. M., d'Alessandro, M., Bergantini, L., Cameli, P., Vantaggiato, L., Bini, L., & Landi, C. (2020). Metabolic dysregulation in idiopathic pulmonary fibrosis. International Journal of Molecular Sciences, 21(16), 5663. https://doi.org/10.3390/ijms21165663
Becker, K. A., Riethmüller, J., Zhang, Y., & Gulbins, E. (2010). The role of sphingolipids and ceramide in pulmonary inflammation in cystic fibrosis. Open Respiratory Medicine Journal, 4, 39-47.
https://doi.org/10.2174/1874306401004010039
Bonfield, T. L., Panuska, J. R., Konstan, M. W., Hilliard, K. A., Hilliard, J. B., Ghnaim, H., et al. (1995). Inflammatory cytokines in cystic fibrosis lungs. American Journal of Respiratory and Critical Care Medicine, 152, 2111-2118. https://doi.org/10.1164/ajrccm.152.6.8520783
Bruscia, E. M., Zhang, P.-X., Ferreira, E., Caputo, C., Emerson, J. W., Tuck, D., et al. (2009). Macrophages directly contribute to the exaggerated inflammatory response in cystic fibrosis transmembrane conductance regulator−/− mice. American Journal of Respiratory Cell and Molecular Biology, 40, 295-304.
https://doi.org/10.1165/rcmb.2008-0170OC
Chang, H., Meng, H. Y., Bai, W. F., & Meng, Q. G. (2021). A metabolomic approach to elucidate the inhibitory effects of baicalin in pulmonary fibrosis. Pharmaceutical Biology, 59(1), 1014-1023.
https://doi.org/10.1080/13880209.2021.1950192
Dechecchi, M. C., Nicolis, E., Norez, C., Bezzerri, V., Borgatti, M., Mancini, I., et al. (2008). Anti-inflammatory effect of miglustat in bronchial epithelial cells. Journal of Cystic Fibrosis, 7, 555-565.
https://doi.org/10.1016/j.jcf.2008.06.002
Dechecchi, M. C., Nicolis, E., Norez, C., Bezzerri, V., Borgatti, M., Mancini, I., ... & Tabary, O. (2011). Modulators of sphingolipid metabolism reduce lung inflammation in cystic fibrosis. American Journal of Respiratory Cell and Molecular Biology, 45(6), 825-833. https://doi.org/10.1165/rcmb.2010-0457OC
Elborn, J. S. (2016). Cystic fibrosis. The Lancet, 388(10059), 2519-2531.
https://doi.org/10.1016/S0140-6736(16)00576-6
Fischer, R., Schwarz, C., Weiser, R., et al. (2022). Evaluating the alginate oligosaccharide (OligoG) as a therapy for Burkholderia cepacia complex cystic fibrosis lung infection. Journal of Cystic Fibrosis, 21, 821-829. https://doi.org/10.1016/j.jcf.2022.01.003
Ghorbani, P., Santhakumar, P., Hu, Q., Djiadeu, P., Wolever, T. M. S., Palaniyar, N., & Grasemann, H. (2015). Short-chain fatty acids affect cystic fibrosis airway inflammation and bacterial growth. European Respiratory Journal, 46(4), 1033-1045. https://doi.org/10.1183/09031936.00143614
Gramegna, A., Magnoni, C., Premuda, C., Alicandro, G., Akkerman, O., Amorim, A., ... & Blasi, F. (2026). Determinants of early Elexacaftor-Tezacaftor-Ivacaor use in adults with cystic fibrosis and preserved lung function: insights from a European multicenter survey. Journal of Cystic Fibrosis. Advance online publication. https://doi.org/10.1016/j.jcf.2026.03.005
Harwood, K. H., McQuade, R. M., Jarnicki, A., & Schneider-Futschik, E. K. (2021). Anti-inflammatory influences of cystic fibrosis transmembrane conductance regulator drugs on lung inflammation in cystic fibrosis. International Journal of Molecular Sciences, 22(14), 7606. https://doi.org/10.3390/ijms22147606
Horati, H., Janssens, H. M., Margaroli, C., Veltman, M., Stolarczyk, M., Kilgore, M. B., ... & Scholte, B. J. (2020). Airway profile of bioactive lipids predicts early progression of lung disease in cystic fibrosis. Journal of Cystic Fibrosis, 19(6), 902-909. https://doi.org/10.1016/j.jcf.2020.01.010
Hou, S., Yue, Q., Hou, X., & Wu, Q. (2025). Targeting the aryl hydrocarbon receptor: The potential of indole compounds in the treatment of cystic fibrosis. International Journal of Molecular Sciences, 26(20), 9876. https://doi.org/10.3390/ijms26209876
Hunter, R. C., Klepac-Ceraj, V., Lorenzi, M. M., Grotzinger, H., Martin, T. R., & Newman, D. K. (2012). Phenazine content in the cystic fibrosis respiratory tract negatively correlates with lung function and microbial complexity. American Journal of Respiratory Cell and Molecular Biology, 47, 738-745.
https://doi.org/10.1165/rcmb.2012-0088OC
Jarosz-Griffiths, H. H., Scambler, T., Wong, C. H., Lara-Reyna, S., Holbrook, J., Martinon, F., et al. (2020). Different CFTR modulator combinations downregulate inflammation differently in cystic fibrosis. eLife, 9.
https://doi.org/10.7554/eLife.54556.sa2
Khan, T. Z., Wagener, J. S., Bost, T., Martinez, J., Accurso, F. J., & Riches, D. W. (1995). Early pulmonary inflammation in infants with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine, 151, 1075-1082. https://doi.org/10.1164/ajrccm/151.4.1075
Konstan, M. W., Hilliard, K. A., Norvell, T. M., & Berger, M. (1994). Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. American Journal of Respiratory and Critical Care Medicine, 150, 448-454. https://doi.org/10.1164/ajrccm.150.2.8049828
Lévêque, M., Le Jeune, A., Jouneau, S., Jan, S., & Catheline, D. (2017). Alterations in lipid membrane composition in CF macrophage may play a role in chronic infections in CF patients. Journal of Cystic Fibrosis, 16(4), 443-453. https://doi.org/10.1016/j.jcf.2016.10.011
Luo, J., Luo, J., Fang, Z., Fu, Y., & Xu, B. (2025). Insights into effects of natural bioactive components on inflammatory diseases in respiratory tract. Phytotherapy Research. Advance online publication. https://doi.org/10.1002/ptr.8367
Makam, M., Diaz, D., Laval, J., Gernez, Y., Conrad, C. K., Dunn, C. E., ... & Tirouvanziam, R. (2009). Activation of critical, host-induced, metabolic and stress pathways marks neutrophil entry into cystic fibrosis lungs. Proceedings of the National Academy of Sciences, 106(14), 5779-5783. https://doi.org/10.1073/pnas.0813410106
Marsh, R., Tricker, J. M., Delhaes, L., Bomberger,J. M., & van der Gast, C. (2026). The gut microbiome: Recent findings and future opportunities in cystic fibrosis. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2026.05.003
Meoli, A., Eickmeier, O., Pisi, G., Fainardi, V., Zielen, S., & Esposito, S. (2022). Impact of CFTR modulators on the impaired function of phagocytes in cystic fibrosis lung disease. International Journal of Molecular Sciences, 23(20), 12421. https://doi.org/10.3390/ijms232012421
Mitri, C., Xu, Z., Bardin, P., Corvol, H., Touqui, L., & Tabary, O. (2020). Novel anti-inflammatory approaches for cystic fibrosis lung disease: Identification of molecular targets and design of innovative therapies. Frontiers in Pharmacology, 11, 1096. https://doi.org/10.3389/fphar.2020.01096
Pailhoriès, H., Velo-Suarez, L., Moalic, Y., et al. (2026). A disrupted microbial network and an ecological shift towards anaerobes in NTM-infected cystic fibrosis patients. Journal of Cystic Fibrosis.
https://doi.org/10.1016/j.jcf.2026.04.005
Palmer, G. C., & Whiteley, M. (2015). Metabolism and pathogenicity of Pseudomonas aeruginosa infections in the lungs of individuals with cystic fibrosis. Microbiology Spectrum, 3(4), MBP-0003-2014.
https://doi.org/10.1128/microbiolspec.MBP-0003-2014
Papa, R., Garzoli, S., Vrenna, G., Sabatino, M., Sapienza, F., Relucenti, M., ... & Ragno, R. (2020). Essential oils biofilm modulation activity, chemical and machine learning analysis-Application on Staphylococcus aureus isolates from cystic fibrosis patients. International Journal of Molecular Sciences, 21(23), 9258.
https://doi.org/10.3390/ijms21239258
Riquelme, S. A., & Prince, A. (2021). Pseudomonas aeruginosa consumption of airway metabolites promotes lung infection. Pathogens, 10(8), 957. https://doi.org/10.3390/pathogens10080957
Scholte, B. J., Horati, H., Veltman, M., Vreeken, R. J., Garratt, L. W., Tiddens, H. A., ... & Stick, S. (2019). Oxidative stress and abnormal bioactive lipids in early cystic fibrosis lung disease. Journal of Cystic Fibrosis, 18(6), 781–789. https://doi.org/10.1016/j.jcf.2019.04.011
Seidl, E., Licht, J. C., Slingers, G., van Koningsbruggen-Rietschel, S., van der Gast, C., Fragoso, C., ... & Grasemann, H. (2026). CFTR modulator therapy with ETI does not significantly alter eNose-derived VOC breath profiles in children with CF. Journal of Cystic Fibrosis. Advance online publication. https://doi.org/10.1016/j.jcf.2026.03.014
Snowball, J., Salem, V., Wu, M., & Blackman, S. M. (2026). Perspectives in cystic fibrosis related diabetes (CFRD) research. Journal of Cystic Fibrosis. Advance online publication.
Taccetti, G., Francalanci, M., Pizzamiglio, G., et al. (2021). Cystic fibrosis: Recent insights into inhaled antibiotic treatment and future perspectives. Antibiotics, 10, 338. https://doi.org/10.3390/antibiotics10030338
Thavamani, A., Salem, I., Sferra, T. J., & Sankararaman, S. (2021). Impact of altered gut microbiota and its metabolites in cystic fibrosis. Metabolites, 11(2), 123. https://doi.org/10.3390/metabo11020123
Trandafir, L. M., Frasinariu, O. E., Tarca, E., Butnariu, L. I., Leon Constantin, M. M., Moscalu, M., ... & Moisa, S. M. (2023). Can bioactive food substances contribute to cystic fibrosis-related cardiovascular disease prevention?. Nutrients, 15(2), 314. https://doi.org/10.3390/nu15020314
Untersmayr, E., Stafflinger-Fürst, E., Heiden, D., Diesner, S. C., Japtok, L., Kleuser, B., ... & Kozelsky-Scholte, L. (2020). Plasma S1P levels are influenced by CFTR function and correlate with clinical symptoms in adult CF patients. Nutrients, 12(3), 765. https://doi.org/10.3390/nu12030765
Yan, F., Wen, Z., Wang, R., Luo, W., Du, Y., Wang, W., & Chen, X. (2017). Identification of the lipid biomarkers from plasma in idiopathic pulmonary fibrosis by Lipidomics. BMC pulmonary medicine, 17(1), 174. https://doi.org/10.1186/s12890-017-0513-4
Rethinking Antimicrobial Strategies: Integrating Microbiome Modulation and Next Generation Therapeutics to Combat Multidrug-Resistant Pathogens
Natural Bioactives and Microbiome Based Precision Therapeutics for Cancer, Chronic, and neurodegenerative diseases
Molecular Epidemiology and Resistance Mechanisms of Extensively Drug-Resistant Gram-Negative Bacteria: Challenges and Emerging Therapeutic Strategies